All In Biotech

NDA 214869 · Avion Pharms

Dhivy

Carbidopa, Levodopa · Oral · Aromatic Amino Acid

Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Nov 12, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

262

53 Phase 3, 16 recruiting

FAERS reports

3,539

2,105 serious, 566 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 21, 2026.

DHIVY is indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. DHIVY is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication ( 1 )

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 12, 2021 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • DHIVY · CARBIDOPA 25MG; LEVODOPA 100MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Carbidopa" as an intervention, any sponsor and status, largest first.

All 262 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hallucination479
  • fall436
  • death370
  • drug ineffective354
  • confusional state217
  • product dose omission issue211
  • dizziness202
  • fatigue199
  • parkinson^s disease195
  • gait disturbance175
  • nausea172
  • tremor170

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20054
20111
201214
201333
201449
201582
2016103
2017170
2018284
2019315
2020430
2021290
2022116
2023470
2024638
2025530
20266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dhivy (Carbidopa/Levodopa)

2024 spending

$979K

Beneficiaries

425

1,703 claims

Per beneficiary

$2,303

$3.04 per unit

View as table
YearSpending
2020$0
2021$0
2022$504,015
2023$994,703
2024$978,958

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 545 on PubMed

Sponsor: Avion Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.